| Literature DB >> 23556028 |
Christoph Kaiser1, Sébastien D S Pion, Michel Boussinesq.
Abstract
OBJECTIVE: A systematic review and meta-analysis of all available case-control studies on the relationship between onchocerciasis and epilepsy. Because age and level of onchocerciasis endemicity in the area of residence are major determinants for infection, an additional analysis was performed, restricted to studies achieving control of these confounding factors. DATA SOURCES: Medical databases, the "African Neurology Database, Institute of Neuroepidemiology and Tropical Neurology, Limoges," reference lists of relevant articles, commercial search engines, up to May 2012.Entities:
Mesh:
Year: 2013 PMID: 23556028 PMCID: PMC3610636 DOI: 10.1371/journal.pntd.0002147
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Design of all eligible studies on the relationship between onchocerciasis and epilepsy by use of a comparison group.
| Year of study, Country [Reference] | Identification/selection of participants | Assessment of diagnosis | No. of Persons included | Control for confounding factors | |||||
| Persons with epilepsy (PWE) | Persons without epilepsy (PWOE) | Epilepsy | Onchocerciasis | PWE | PWOE | IoE | ToE | Sex | |
| 1991, Cameroon | Lists made by community leaders+ITW | Inhabitants without history of seizures identified in parasitological survey | Non-standardized ITW performed by MD | Nod q, Nod Q, mf q, mf Q | 72 | 72 |
|
|
|
| 1993, Uganda | ITW | Household members without history of seizures | Non-standardized ITW performed by MD | Nod q+mf q | 39 | 946 |
|
|
|
| 1994, Burundi | Lists produced by local authorities and health center staff | Relatives of PWE from the same household | Non-standardized ITW performed by MD | mf q, serology | 110 | 82 |
|
|
|
| 1994, Uganda | PWE aged 10–19 years identified in a population-wide survey | Inhabitants without seizures identified in parasitological survey, age 10–23 y | SITW and NE performed by MD | Nod q, Nod Q, mf q | 38 | 38 |
|
|
|
| 1995, Benin | Random household sample, Door-to-door survey | Household members without history of seizures | Non-standardized ITW and NE by neurologist | mf q | 13 | 517 |
|
|
|
| 1996, Burkina Faso | Population-wide survey, ITW | All inhabitants aged >14 years without history of seizures | SITW performed by health personnel | mf q | 34 | 2006 |
|
|
|
| 1996, CAR | Identification of PWE >14 years by health personnel and village leaders | Inhabitants without neurologic illness, age >14 years | SITW and NE by neurologist | mf q, mf Q | 187 | 374 |
|
|
|
| 1996, Tanzania | Participants of oncho. survey with history of epileptic seizures | Participants of oncho. survey without seizure history | SITW performed by MD | mf q | 34 | 380 |
|
|
|
| 1998, Mali | Population-wide survey, ITW | Inhabitants without history of seizures aged >7 years | SITW and NE by neurologist | mf q | 70 | 140 |
|
|
|
| 2000, Cameroon | Identification of PWE by community key persons, age <34 years | Inhabitants attending for other illness, age <34 years | SITW by MD | Nod q, mf q, mf Q | 83 | 53 |
|
|
|
| 2004, Cameroon | Door-to-door survey in one village, ITW | Subjects without history of seizures selected at random from participating households | SITW by MD trained in neurology+review by neurologists | Nod q | 18 | 36 |
|
|
|
| 2005, Tanzania | PWE attending specific epilepsy clinic | Relatives of PWE without history of seizures | SITW and NE by neurologist | mf q, mf Q, skin PCR | 196 | 104 |
|
|
|
| 2005, Cameroon | Identification in one village by health authorities | Not specified | Not specified | Circulating antigens | 54 | 98 |
|
|
|
Assessment of Epilepsy: ITW = interview; MD = medical doctor; NE = neurologic examination; SITW = standardized interview;
Assessment of Onchocerciasis: Nod q = examination for presence of nodule(s); Nod Q = assessment of number of nodules; mf q = microscopic examination for presence of microfilariae in skin biopsies (no count); mf Q = assessment of skin microfilarial density; Nod+mf q = assessment of presence of nodules OR of mf; PCR = detection of parasite DNA in skin biopsy by using polymerase chain reaction.
Control for confounding factors: IoE = Intensity of exposure (residence); ToE = Time of exposure (age/duration of residence).
The article by Kabore et al. [33] reports data from only 5 of the 12 villages for which data are given in reference [34] and [35].
Patients without skin microfilariae but having experienced a reaction to ivermectin treatment within 1 year were also considered infected.
Results of eye examinations were reported in this study but are not considered in the present analysis.
Case-control studies on the onchocerciasis-epilepsy relationship: study areas characteristics and odds ratios (OR).
| [Reference] | Pre-control onchocerciasis endemicity level | Duration of onchocerciasis control before study (years) | Onchocerciasis endemicity level at time of study | OR mf (95% CI) | OR Nod (95% CI) |
|
| Hyper (Pmf>69%) | 0 | Hyper (Pmf>69%) | 4.17 (0.45–38.32) | 2.82 (1.43–5.56) |
|
| 7 villages hyper, 6 meso/hypo | 3 CDTI | 7 hyper (Pmf>60%), 6 meso/hypo | 1.67 (0.61–4.57) | 2.77 (0.92–8.33) |
|
| Area meso/hyper | 5 CDTI | Meso/hyper | 1.17 (0.82–1.68) | NA |
|
| 7 villages hypo, 11 meso/hyper | 11 CDTI+VC for 4 years (1994–1997) | All hypo (Pmf 9% and 23%) | 2.04 (0.40–10.40) | NA |
|
| 1 village hyper, 1 village hypo | 2 CDTI | 1 hyper (Pmf 63%), 1 hypo (Pmf 19%) | 7.31 (3.19–16.73) | NA |
|
| Area meso/hyper | 0 | Meso/hyper | 2.49 (1.38–4.50) | NA |
|
| Area meso/hyper | 1 CDTI+VC for 7 years (1988–1995) | Meso (Pmf 47%) | 2.56 (0.78–8.41) | NA |
|
| Area hyper | VC for 16 years (1975–1990) | Hypo (Pmf 13%) | 0.84 (0.29–2.40) | NA |
|
| Area hyper | 0 | Hyper (Pmf 68%) | 3.50 (1.21–10.17) | NA |
|
| Area hyper | 1 CDTI | Hyper (Pmf>80%) | 3.76 (1.31–10.74) | 0.98 (0.55–1.75) |
|
| Area hyper | 3 CDTI | Hyper (PNod 62.5%) | NA | 1.38 (0.42–4.51) |
|
| Area meso/hyper | 8 CDTI | Meso | 3.77 (2.18–6.52) | NA |
| Pooled studies (random effects model) | 2.49 (1.61–3.86) | 1.74 (0.94–3.20) |
The first four studies are those achieving control for intensity and time of exposure and gender. In these studies people with epilepsy were matched for gender, age and place of residence to one or two people without epilepsy; in the study by Kaiser et al. (2011), 5 of 38 pairs were not matched for sex.
Pmf = prevalence of skin microfilariae (mf) in subjects aged ≥5 years; PNod = prevalence of nodules in males aged ≥20 years; Hypo = hypoendemic (Pmf<35% or PNod<20%); Meso = mesoendemic (35%≤Pmf<60% or 20%≤PNod <40%); Hyper = hyperendemic (Pmf≥60% or PNod≥40%).
CDTI = Community-Directed Treatment with Ivermectin; VC = Vector control.
OR mf = Odds ratio for epilepsy in patients with skin mf; OR Nod = Odds ratio for epilepsy in patients with nodules; 95%CI = 95% Confidence interval; NA = not assessable.
Passive ivermectin treatment had been organized in these areas before the implementation of the CDTIs organized by the African Program for Onchocerciasis Control (APOC).
OR calculated on the number of persons examined (6 of the 36 controls were “missing” for nodule palpation). If all the missing controls had nodules, the OR would be 1.00 (0.31–3.19) and if none of them had nodules, the OR would be 1.96 (0.62–6.22).
Results of studies utilizing supplementary methods for assessment of O. volvulus infection (serology, polymerase chain reaction, circulating antigen).
| Country, Year of study [Reference] | Method of assessment | Persons with epilepsy (PWE) | Persons without epilepsy (PWOE) | Odds ratio (95% CI) | P value | ||
| 1994, Burundi | n = 110 | n = 82 | |||||
| Oncho + | Oncho − | Oncho + | Oncho − | ||||
| Skin scarification alone | 69 | 41 | 33 | 49 | 2.49 (1.38–4.50) | p = 0.001 | |
| Skin scarification and Serology combined | 90 | 20 | 56 | 26 | 2.09 (1.07–4.09) | p = 0.023 | |
| 2005, Tanzania | n = 200 (196) | n = 100 (104) | |||||
| Oncho + | Oncho − | Oncho + | Oncho − | ||||
| Skin snip alone | 103 | 97 | 22 | 78 | 3.77 (2.18–6.52) | p<0.0001 | |
| Skin snip and skin PCR combined | 135 | 61 | 35 | 69 | 4.36 (2.62–7.24) | P<0.0001 | |
| 2005, Cameroon | n = 441 | n = 98 | |||||
| Oncho + | Oncho − | Oncho + | Oncho − | ||||
| Circulating antigens | 78 | 363 | 15 | 83 | 1.19 (0.65–2.17) | p = 0.29 | |
n = number of persons examined.
Oncho + = No. of persons with positive onchocerciasis infection status; Oncho − = No. of persons with negative onchocerciasis infection status.
Numbers of persons examined differed slightly between reports from this study. Data for skin snip results alone are presented as given in reference [37], and for skin snip and skin PCR results combined as given in reference [36].
Case-control studies on the onchocerciasis-epilepsy relationship: results of studies controlling for confounders.
| Method of assessment | Reference | Persons with epilepsy (PWE) | Persons without epilepsy (PWOE) | Odds ratio (95% CI) | SMD | P value | ||
| Skin biopsy | ||||||||
| Qualitative | No. mf+ | No. mf− | No. mf+ | No. mf− | ||||
| Druet-Cabanac et al. | 74 | 113 | 134 | 240 | 1.17 (0.82–1.68) | |||
| Farnarier et al. | 3 | 67 | 3 | 137 | 2.05 (0.40–10.40) | |||
| Boussinesq et al. | 71 | 1 | 68 | 4 | 4.18 (0.45–38.32) | |||
| Kaiser et al. | 29 | 9 | 25 | 13 | 1.68 (0.61–4.57) | |||
| Pooled result (random effects) | 1.29 (0.93–1.79) | p = 0.139 | ||||||
| Quantitative | Mean mf density (±SD) | Mean mf density (±SD) | ||||||
| Druet-Cabanac et al. | 26±42 | 28±48 | n.r. | |||||
| Boussinesq et al. | 288±274 | 141±173 | <0.0001 | |||||
| Pooled result (random effects) | 0.28 (−0.39–0.96) | 0.407 | ||||||
| Nodule palpation | ||||||||
| Qualitative | No. Nod+ | No. Nod − | No. Nod+ | No. Nod − | ||||
| Kaiser et al. | 11 | 23 | 5 | 29 | 2.77 (0.92–8.33) | 0.065 | ||
| Pion et al. | 49 | 23 | 31 | 41 | 2.82 (1.43–5.56) | 0.005 | ||
| Pooled result (random effects) | 2.80 (1.57–5.00) | <0.001 | ||||||
| Quantitative | Mean No. of Nod (±SD) | Mean No. of Nod (±SD) | ||||||
| Kaiser et al. | 0.45±0.72 | 0.18±0.45 | 0.061 | |||||
| Pion et al. | 1.14±1.04 | 0.82±1.30 | 0.187 | |||||
| Pooled result (random effects) | 0.384 (0.02–0.745) | 0.037 | ||||||
SMD = Standardized Mean Difference; SD = Standard deviation.
No. mf+/No. mf− = Number of persons with/without microfilaria in skin biopsy; No. Nod +/No. Nod − = Number of persons with/without palpable nodule.
Results of eye examinations not considered.
Mantel-Haenszel weighted summary Odds ratio.
n.r. = not reported in original study [30].
Test of Cohen's Standardized Mean Difference [23].